{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:48:29Z","timestamp":1790772509237,"version":"4.1.0"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Hypertension"],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>cGMP MANP (M-atrial natriuretic peptide) is a best-in-class activator of the pGC-A (particulate guanylyl cyclase A) receptor. Furosemide increases the effectiveness of antihypertensive agents, but activates renin-angiotensin-aldosterone system. We aimed to investigate for the first time cardiorenal and neurohumoral actions of MANP in a genetic model of hypertension in spontaneously hypertensive rats. We also assessed how MANP would potentiate the blood pressure (BP)\u2013lowering actions of furosemide while reducing the production of aldosterone.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Spontaneously hypertensive rats (N=60) were randomized in vehicle, MANP, furosemide, or MANP+furosemide groups. Furosemide (1, 5, 10 mg\/kg) was given as a single bolus which in MANP+furosemide groups was followed by a 60-minute infusion of MANP.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>\n              BP was reduced in MANP300 (300 pmol\/[kg\u00b7min]) and MANP600 (600 pmol\/[kg\u00b7min]) groups (\n              <jats:italic>P<\/jats:italic>\n              &lt;0.05) and was accompanied by significant increase in plasma cyclic guanosine monophosphate. Furosemide alone reduced BP but less compared with MANP with no change in plasma cyclic guanosine monophosphate. MANP+furosemide resulted in the greatest BP reduction and significant increase in plasma cyclic guanosine monophosphate in Fs5+MANP300, Fs10+MANP300, and Fs10+MANP600. Plasma aldosterone increased in furosemide groups, which was significantly attenuated in MANP+furosemide groups. Natriuresis and diuresis increased in all treated groups (\n              <jats:italic>P<\/jats:italic>\n              &lt;0.05) with no significant differences between furosemide and furosemide+MANP. In vitro, MANP increased cyclic guanosine monophosphate level in human vascular cells.\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>We provide novel evidence that MANP potentiates the BP-lowering actions of furosemide, suppresses the activation of renin-angiotensin-aldosterone system, and preserves renal function. These data are highly relevant to clinical needs in the treatment of hypertension and heart failure.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1161\/hypertensionaha.121.18837","type":"journal-article","created":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T10:00:33Z","timestamp":1642672833000},"page":"750-760","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":9,"title":["MANP (M-Atrial Natriuretic Peptide) Reduces Blood Pressure and Furosemide-Induced Increase in Aldosterone in Hypertension"],"prefix":"10.1161","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9345-679X","authenticated-orcid":true,"given":"Nina A.","family":"Dzhoyashvili","sequence":"first","affiliation":[{"name":"Cardiorenal Research Laboratory, Department of Cardiovascular Medicine (N.A.D., S.R.I., H.H.C., J.C.B.), Mayo Clinic, Rochester, MN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seethalakshmi R.","family":"Iyer","sequence":"additional","affiliation":[{"name":"Cardiorenal Research Laboratory, Department of Cardiovascular Medicine (N.A.D., S.R.I., H.H.C., J.C.B.), Mayo Clinic, Rochester, MN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2315-0330","authenticated-orcid":true,"given":"Horng H.","family":"Chen","sequence":"additional","affiliation":[{"name":"Cardiorenal Research Laboratory, Department of Cardiovascular Medicine (N.A.D., S.R.I., H.H.C., J.C.B.), Mayo Clinic, Rochester, MN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"John C.","family":"Burnett","sequence":"additional","affiliation":[{"name":"Cardiorenal Research Laboratory, Department of Cardiovascular Medicine (N.A.D., S.R.I., H.H.C., J.C.B.), Mayo Clinic, Rochester, MN."},{"name":"Department of Physiology and Biomedical Engineering (J.C.B.), Mayo Clinic, Rochester, MN."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2009.04.080"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M109.010777"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.110.159210"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.113.000206"},{"key":"e_1_3_3_6_2","first-page":"127","volume-title":"In: Heart Failure: A Companion to Braunwald\u2019s Heart Disease","author":"Dzhoyashvili N","year":"2019","unstructured":"Dzhoyashvili, N, Burnett, JC, Jr. Natriuretic peptides in heart failure: pathologic and therapeutic implications. Felker, GM, Mann, D, eds. In: Heart Failure: A Companion to Braunwald\u2019s Heart Disease. 4th ed. Elsevier; 2019:127\u2013136.","edition":"4"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00109-011-0801-z"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.05.049"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.121.17159"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.121.18264"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000596"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-7176.2011.00512.x"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-7176.2011.00564.x"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.009149"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00476.2015"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-139-4-200308190-00006"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67814-2"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYP.0000000000000090"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12917-020-02451-y"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.00286.2017"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.00233.2012"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01473295"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1038\/ng.361"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2011.05.011"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0189858"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.hyp.23.6.903"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI23360"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.1992.263.2.E181"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000124064.00494.21"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.2008.153916"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2013.110"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1080\/08860220701641777"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1038\/324473a0"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1159\/000345243"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.115.002505"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejheart.2007.07.011"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.100.12.1311"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1159\/000164149"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00257-3"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jnma.2017.06.008"}],"container-title":["Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/HYPERTENSIONAHA.121.18837","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T10:05:24Z","timestamp":1715594724000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/HYPERTENSIONAHA.121.18837"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["10.1161\/HYPERTENSIONAHA.121.18837"],"URL":"https:\/\/doi.org\/10.1161\/hypertensionaha.121.18837","relation":{},"ISSN":["0194-911X","1524-4563"],"issn-type":[{"value":"0194-911X","type":"print"},{"value":"1524-4563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"2021-12-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-05","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}